Verition Fund Management
RXRX icon

Verition Fund Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Verition Fund Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.62M Buy
441,400
+35,700
+9% +$119K 0.01% 1206
2026
Q1 		$1.25M Hold
405,700
– – 0.01% 1226
2025
Q4 		$1.66M Sell
405,700
-51,000
-11% -$253K 0.01% 1772
2025
Q3 		$2.23M Buy
456,700
+184,700
+68% +$970K 0.01% 1879
2025
Q2 		$1.38M Buy
+272,000
New +$1.34M 0.01% 2229

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Verition Fund Management's RXRX Position: Q2 2026 in Review

Verition Fund Management increased its Recursion Pharmaceuticals (RXRX) stake by 8.3% in Q2 2026, buying an estimated $114K and bringing the position to 446,947 shares worth $1.64M. The position accounts for 0.01% of the portfolio, ranked #1202.

Verition Fund Management first reported a position in RXRX in Q1 2023 and has held it in 7 quarters since. The position peaked at $1.69M in Q4 2025. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Verition Fund Management held 446,947 shares of Recursion Pharmaceuticals worth $1.64M as of Q2 2026.
  • Verition Fund Management bought 34,200 Recursion Pharmaceuticals shares in Q2 2026, an estimated $114K.
  • Recursion Pharmaceuticals made up 0.01% of Verition Fund Management's portfolio in Q2 2026, its #1202 holding.
  • Verition Fund Management first reported a position in Recursion Pharmaceuticals in Q1 2023 and has held it in 7 quarters since.
  • Verition Fund Management's Recursion Pharmaceuticals position peaked at $1.69M in Q4 2025.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Verition Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.